Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN(R) in Combination with the Redox Modulating Agent Motexafin Gadolinium (MGd) - Marketwatch

HENDERSON, Nev., May 17, 2012 (BUSINESS WIRE) -- --MGd Shown to Have Synergistic Effect with ZEVALIN and Clinical Activity in a Variety of Tumors --Spectrum Pipeline Includes Phase 3 Trial of ZEVALIN as a Single Dose in Diffuse Large B-Cell ...

Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN® in Combination with the Redox Modulating Agent Motexafin Gadolinium (MGd) - Yahoo Finance

Spectrum Pharmaceuticals (NasdaqGS: SPPI - News), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study ...

Spectrum Pharma Begins Phase 2 Study Of ZEVALIN Injection - Quick Facts - RTT News

(RTTNews) - Spectrum Pharmaceuticals (SPPI: News ) announced the initiation of a Phase 2 study evaluating ZEVALIN Injection for intravenous use + rituximab in combination with motexafin gadolinium or MGd in patients with rituximab-refractory low-grade or ...

Spectrum extends tender offer for Allos Therapeutics amid FTC inquiry - The Business Journal

Spectrum Pharmaceuticals Inc. Spectrum Pharmaceuticals Inc. Latest from The Business Journals Nevada company buying Allos Therapeutics Baltimore’s Cangene Biopharma sued over cancer drug’s production glitch FDA OKs Spectrum’s Zevalin as ...

Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics - Marketwatch

About Spectrum Pharmaceuticals, Inc. Spectrum Pharmaceuticals, a biotechnology company with a primary focus in oncology and hematology, currently markets two oncology drugs, FUSILEV(R) (levoleucovorin) for Injection and ZEVALIN(R) (ibritumomab ...

Spectrum Pharmaceuticals Reports Record Revenues and Profits for First Quarter of 2012 - Boston Globe

ZEVALIN (ibritumomab tiuxetan) injection for intravenous use, is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL). ZEVALIN is also indicated for the treatment of ...

5 Biotech Stocks At Rock Bottom Price With Takeover Possibility - Seekingalpha.com

Spectrum currently markets two oncology drugs, FUSILEV (levoleucovorin) for Injection and ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use. In addition, Spectrum has two drugs, apaziquone and belinostat, in late stage development. The company ...

Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics - PharmiWeb

About Spectrum Pharmaceuticals, Inc. Spectrum Pharmaceuticals, a biotechnology company with a primary focus in oncology and hematology, currently markets two oncology drugs, FUSILEV® (levoleucovorin) for Injection and ZEVALIN® (ibritumomab tiuxetan ...

BUYINS.NET: MEDW, MSPD, TESS, XEC, SNMX, SPPI Are Seasonally Ripe To Go Down In the Next Five Weeks - TMCnet

It markets two oncology drugs, ZEVALIN and FUSILEV; and also has two drugs in late stage development, apaziquone and belinostat, along with a diverse pipeline. The company was formerly known as NeoTherapeutics, Inc. and changed its name to ...